Northview Acquisition in an amended S-1 registration disclosed it now plans to offer 15 million units, at $10 each, down from 18 million initially planned when the offering was filed in June.
A unit still consists of one share of common stock and one-half of a warrant, but has now been sweetened with a right good for one-teneth of a share.
I-Bankers Securities is sole book-running manager for the offering. Dawson James is co-manager.
The SPAC expects to target small-cap healthcare companies that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space.
Northview is led by Co-Founder, Director and CEO Jack Stover, who was previously president and CEO of Interpace Biosciences.
The SPAC intends to apply for a Nasdaq listing under ticker symbol NVACU. Read more.
